My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Tadalafil Research Chemical

Tadalafil Research Chemical


tadalafil research chemical relaxes muscles found in the walls of blood vessels and increases blood flow to particular areas of the body.Tadalafil under the name of Cialis is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy. Another brand of tadalafil is Adcirca, which is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women.Do not take Cialis while also taking Adcirca, unless your doctor tells you to.Tadalafil may also be used for purposes not listed in this medication guide.

Tadalafil research chemical side effects          

  • headache.
  • indigestion.
  • back pain.
  • muscle pain.
  • flushing.
  • stuffy nose.

Drug interactions

Since PDE5 inhibitors such as tadalafil research chemical may cause transiently low blood pressure (hypotension), alkyl nitrites should not be taken for at least 48 hours after taking the last dose of tadalafil research chemical. Using poppers within this timeframe may increase the risk of life-threatening hypotension.

Since people who have taken tadalafil research chemical within the past 48 hours cannot take organic nitrates to relieve anginathese patients should seek immediate medical attention if they experience anginal chest pain. In the event of a medical emergency, paramedics and medical personnel should be notified of any recent doses of tadalafil.


This product is a very potent chemical. This product is NOT for human use and can be harmful if ingested. This product is for research/laboratory use only. This product is NOT in a sterile solution and is NOT to be injected. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and should not be misbranded, misused or mislabeled as a drug, food or cosmetic.


In vitro results suggested that tadalafil would have little effect on the pharmacokinetics of drugs metabolized by CYP3A. Clinical studies demonstrated that the pharmacokinetics of 2 different CYP3A substrates, midazolam and lovastatin, were virtually unchanged after tadalafil coadministration. Thus therapeutic concentrations of tadalafil do not produce clinically significant changes in the clearance of drugs metabolized by CYP3A.